JP2018523676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523676A5 JP2018523676A5 JP2018508149A JP2018508149A JP2018523676A5 JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5 JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5
- Authority
- JP
- Japan
- Prior art keywords
- histidine
- hcl
- aniflorumab
- polysorbate
- trehalose dihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 3
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 229960003646 lysine Drugs 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229940074409 trehalose dihydrate Drugs 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207164P | 2015-08-19 | 2015-08-19 | |
| US62/207,164 | 2015-08-19 | ||
| PCT/US2016/047506 WO2017031288A1 (en) | 2015-08-19 | 2016-08-18 | Stable anti-ifnar1 formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104494A Division JP7035119B2 (ja) | 2015-08-19 | 2020-06-17 | 安定な抗ｉｆｎａｒ１製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523676A JP2018523676A (ja) | 2018-08-23 |
| JP2018523676A5 true JP2018523676A5 (enExample) | 2020-04-23 |
| JP6720293B2 JP6720293B2 (ja) | 2020-07-08 |
Family
ID=58052002
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508149A Active JP6720293B2 (ja) | 2015-08-19 | 2016-08-18 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2020104494A Active JP7035119B2 (ja) | 2015-08-19 | 2020-06-17 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2022031581A Pending JP2022066345A (ja) | 2015-08-19 | 2022-03-02 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2024140769A Pending JP2024161043A (ja) | 2015-08-19 | 2024-08-22 | 安定な抗ｉｆｎａｒ１製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104494A Active JP7035119B2 (ja) | 2015-08-19 | 2020-06-17 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2022031581A Pending JP2022066345A (ja) | 2015-08-19 | 2022-03-02 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2024140769A Pending JP2024161043A (ja) | 2015-08-19 | 2024-08-22 | 安定な抗ｉｆｎａｒ１製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10125195B2 (enExample) |
| EP (3) | EP4233892A3 (enExample) |
| JP (4) | JP6720293B2 (enExample) |
| KR (4) | KR20220127378A (enExample) |
| CN (1) | CN107921109A (enExample) |
| AU (3) | AU2016308262C1 (enExample) |
| CA (1) | CA2995222C (enExample) |
| CY (2) | CY1123657T1 (enExample) |
| DK (2) | DK3769781T5 (enExample) |
| ES (2) | ES2818229T3 (enExample) |
| FI (1) | FI3769781T3 (enExample) |
| HR (2) | HRP20230463T1 (enExample) |
| HU (2) | HUE051862T2 (enExample) |
| IL (1) | IL257279B2 (enExample) |
| LT (2) | LT3337502T (enExample) |
| PL (2) | PL3337502T3 (enExample) |
| PT (2) | PT3337502T (enExample) |
| RS (2) | RS64263B1 (enExample) |
| RU (1) | RU2731737C2 (enExample) |
| SG (1) | SG10202106970XA (enExample) |
| SI (2) | SI3769781T1 (enExample) |
| SM (2) | SMT202300176T1 (enExample) |
| WO (1) | WO2017031288A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| US20200061015A1 (en) * | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| KR102766960B1 (ko) * | 2019-11-11 | 2025-02-11 | 아스트라제네카 아베 | 전신성 홍반성 루푸스에서 i형 인터페론 억제 |
| AU2021279277A1 (en) | 2020-05-29 | 2023-02-02 | Astrazeneca Ab | Treatment of cardiometabolic disease with inhibitors of type I interferon signalling |
| IL299215A (en) | 2020-06-25 | 2023-02-01 | Medimmune Ltd | Prevention of axonal damage through binding of an antibody to amyloid beta 1-42 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| CN117157099A (zh) * | 2021-04-23 | 2023-12-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| JP2024519196A (ja) | 2021-04-23 | 2024-05-09 | アストラゼネカ・アクチエボラーグ | 皮膚エリテマトーデスの処置 |
| US20250002590A1 (en) | 2021-04-23 | 2025-01-02 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| LT4114465T (lt) * | 2021-04-23 | 2023-11-10 | Astrazeneca Ab | Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai |
| JP2024516886A (ja) | 2021-05-12 | 2024-04-17 | アストラゼネカ・アクチエボラーグ | 全身性エリテマトーデス患者における１型インターフェロン受容体阻害剤のステロイド節約 |
| CN113521276B (zh) * | 2021-07-13 | 2022-04-12 | 江苏荃信生物医药股份有限公司 | 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂 |
| CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
| WO2023284073A1 (zh) * | 2021-07-13 | 2023-01-19 | 江苏荃信生物医药股份有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂 |
| EP4377349A1 (en) | 2021-07-27 | 2024-06-05 | Astrazeneca AB | Treatment of lupus |
| CA3233069A1 (en) | 2021-10-04 | 2023-04-13 | Astrazeneca Ab | Treatment of lupus |
| EP4422674A4 (en) * | 2021-10-29 | 2025-09-17 | Intas Pharmaceuticals Ltd | Stable lyophilized formulation of an anti-alpha 4beta7 antibody |
| TW202337497A (zh) * | 2022-02-18 | 2023-10-01 | 中國大陸商重慶明道浩悅生物科技有限公司 | 鼻內調配物及抗sars-cov-2棘蛋白抗體 |
| IN202221038828A (enExample) * | 2022-07-06 | 2024-01-12 | ||
| CN120344259A (zh) | 2022-10-13 | 2025-07-18 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| CN121127499A (zh) | 2023-05-19 | 2025-12-12 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| EP1781705B1 (en) * | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101553504A (zh) | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| CA2692165A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| HUE028958T2 (en) * | 2008-02-08 | 2017-01-30 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| EP2358392B1 (en) * | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| KR20140103099A (ko) | 2011-10-12 | 2014-08-25 | 아센디스 파마 옵탈몰로지 디비젼 에이/에스 | 안구 병태의 예방 및 치료 |
| CA2951856A1 (en) | 2011-10-28 | 2013-05-02 | Integritybio Inc. | Protein formulations containing amino acids |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| BR112015008186A2 (pt) * | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
| EP2997036B1 (en) | 2013-05-15 | 2021-03-03 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US20160250329A1 (en) | 2013-10-29 | 2016-09-01 | Albumedix A/S | Antibody composition |
| AU2015310879A1 (en) | 2014-09-03 | 2017-03-02 | Medimmune Limited | Stable anti-IL-4R-alpha antibody formulation |
| WO2016109822A1 (en) | 2014-12-31 | 2016-07-07 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
-
2016
- 2016-08-18 RS RS20230447A patent/RS64263B1/sr unknown
- 2016-08-18 LT LTEP16837818.0T patent/LT3337502T/lt unknown
- 2016-08-18 ES ES16837818T patent/ES2818229T3/es active Active
- 2016-08-18 KR KR1020227031079A patent/KR20220127378A/ko not_active Ceased
- 2016-08-18 PL PL16837818T patent/PL3337502T3/pl unknown
- 2016-08-18 PT PT168378180T patent/PT3337502T/pt unknown
- 2016-08-18 DK DK20174805.0T patent/DK3769781T5/da active
- 2016-08-18 PT PT201748050T patent/PT3769781T/pt unknown
- 2016-08-18 RU RU2018107725A patent/RU2731737C2/ru active
- 2016-08-18 EP EP23160045.3A patent/EP4233892A3/en active Pending
- 2016-08-18 CA CA2995222A patent/CA2995222C/en active Active
- 2016-08-18 SM SM20230176T patent/SMT202300176T1/it unknown
- 2016-08-18 HR HRP20230463TT patent/HRP20230463T1/hr unknown
- 2016-08-18 IL IL257279A patent/IL257279B2/en unknown
- 2016-08-18 RS RS20201103A patent/RS60773B1/sr unknown
- 2016-08-18 DK DK16837818.0T patent/DK3337502T3/da active
- 2016-08-18 JP JP2018508149A patent/JP6720293B2/ja active Active
- 2016-08-18 AU AU2016308262A patent/AU2016308262C1/en active Active
- 2016-08-18 HU HUE16837818A patent/HUE051862T2/hu unknown
- 2016-08-18 EP EP16837818.0A patent/EP3337502B1/en active Active
- 2016-08-18 ES ES20174805T patent/ES2947488T3/es active Active
- 2016-08-18 CN CN201680047012.7A patent/CN107921109A/zh active Pending
- 2016-08-18 SM SM20200483T patent/SMT202000483T1/it unknown
- 2016-08-18 WO PCT/US2016/047506 patent/WO2017031288A1/en not_active Ceased
- 2016-08-18 HR HRP20201297TT patent/HRP20201297T1/hr unknown
- 2016-08-18 EP EP20174805.0A patent/EP3769781B1/en active Active
- 2016-08-18 SI SI201631699T patent/SI3769781T1/sl unknown
- 2016-08-18 SI SI201630900T patent/SI3337502T1/sl unknown
- 2016-08-18 KR KR1020187007314A patent/KR102168005B1/ko active Active
- 2016-08-18 PL PL20174805.0T patent/PL3769781T3/pl unknown
- 2016-08-18 KR KR1020207029325A patent/KR102669174B1/ko active Active
- 2016-08-18 FI FIEP20174805.0T patent/FI3769781T3/fi active
- 2016-08-18 HU HUE20174805A patent/HUE061985T2/hu unknown
- 2016-08-18 US US15/240,224 patent/US10125195B2/en active Active
- 2016-08-18 KR KR1020247016705A patent/KR20240090616A/ko active Pending
- 2016-08-18 SG SG10202106970XA patent/SG10202106970XA/en unknown
- 2016-08-18 LT LTEP20174805.0T patent/LT3769781T/lt unknown
-
2020
- 2020-05-21 AU AU2020203306A patent/AU2020203306C1/en active Active
- 2020-06-17 JP JP2020104494A patent/JP7035119B2/ja active Active
- 2020-09-11 CY CY20201100860T patent/CY1123657T1/el unknown
-
2021
- 2021-10-26 AU AU2021257915A patent/AU2021257915A1/en not_active Abandoned
-
2022
- 2022-03-02 JP JP2022031581A patent/JP2022066345A/ja active Pending
-
2023
- 2023-06-20 CY CY20231100289T patent/CY1126062T1/el unknown
-
2024
- 2024-08-22 JP JP2024140769A patent/JP2024161043A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523676A5 (enExample) | ||
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| EP3316928A4 (en) | AUTOMATIC INJECTORS FOR THE ADMINISTRATION OF A MEDICAMENT IN A PREPARED SYRINGE | |
| HRP20211371T1 (hr) | Stabilne, vodene formulacije protutijela | |
| JP2015057451A5 (enExample) | ||
| EA201792591A1 (ru) | Фармацевтические препараты | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| JP2015110588A5 (enExample) | ||
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| JP2019516735A5 (enExample) | ||
| EA201891606A1 (ru) | Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона | |
| HRP20191137T1 (hr) | Formulacije otopina konstruiranih anti-il-23p19 antitijela | |
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| JP2016510326A5 (enExample) | ||
| PE20170773A1 (es) | Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| JP2016515623A5 (enExample) | ||
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| EA201892837A1 (ru) | Физиологически сбалансированные составы для инъекций, включающие фоснетупитант | |
| FI3733712T3 (fi) | Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä | |
| EA201890788A1 (ru) | Препараты оланзапина с замедленным высвобождением | |
| JP2014058509A5 (enExample) |